<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676647</url>
  </required_header>
  <id_info>
    <org_study_id>18077</org_study_id>
    <secondary_id>NCI-2018-01910</secondary_id>
    <secondary_id>18077</secondary_id>
    <nct_id>NCT03676647</nct_id>
  </id_info>
  <brief_title>Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules</brief_title>
  <official_title>Retrospective-Prospective Collection of Thyroid Specimens After FNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature
      works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing,
      such as the diagnostic DNA methylation signature, may be a less invasive way to check for
      thyroid cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To validate a novel epigenetic thyroid nodule diagnostic test, diagnostic DNA methylation
      signature (DDMS) in a retrospective-prospective study with leftover of fine needle aspiration
      biopsies.

      OUTLINE:

      Previously collected FNA aspiration specimen samples are analyzed via DDMS assay.
      Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS
      assay.

      After completion of study, patients are followed up yearly for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 27, 2020</start_date>
  <completion_date type="Anticipated">December 27, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Sensitivity of the diagnostic deoxyribonucleic acid (DNA) methylation signature (DDMS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be assessed by taking the ratio of the number of thyroid cancer specimens diagnosed as cancer using the DDMS and the total number of thyroid cancer specimens according to the final diagnosis. Will determine the 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of DDMS</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be assessed by taking the ratio of the number of benign nodules diagnosed by DDMS and the total number of benign thyroid nodule specimens according to the final diagnosis. Will determine the 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive predictive value (PPV)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will calculate PPV by dividing the number of true thyroid cancer specimens by the number of thyroid cancer diagnosis by DDMS. Will determine the 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative predictive value (NPV)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will calculate NPV by dividing the number of benign nodules by the number of benign diagnosis by DDMS. Will determine the 95% confidence intervals.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Thyroid Gland Nodule</condition>
  <arm_group>
    <arm_group_label>Diagnostic (biospecimen collection)</arm_group_label>
    <description>Previously collected FNA aspiration specimen samples are analyzed via DDMS assay. Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic DNA Methylation Signature</intervention_name>
    <description>Undergo collection of tissue samples</description>
    <arm_group_label>Diagnostic (biospecimen collection)</arm_group_label>
    <other_name>DDMS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People undergoing fine needle aspiration.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing FNA for thyroid nodule diagnosis.

          -  Any race and ethnicity are eligible for the study.

          -  Patient should have thyroid nodule(s) with indeterminate diagnosis after FNA (Bethesda
             category of indeterminate FNA [III-V]).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Hahn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Hahn, PhD</last_name>
      <phone>626-256-4673</phone>
      <email>mhahn@coh.org</email>
    </contact>
    <investigator>
      <last_name>Maria Hahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Nodule</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

